{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:16:22Z","timestamp":1780528582655,"version":"3.54.1"},"reference-count":20,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"unspecified","delay-in-days":67,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Trans. Sci."],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>Composite endpoints can encode multiple pieces of information and are increasingly adopted in clinical trials. Advocacy for using composite endpoints began decades ago in cardiovascular trials, leading to incorporation of patient-oriented outcomes and consideration of a hierarchical ranking system. The use of composite endpoints in coronavirus disease (COVID-19) trials has evolved similarly. We conducted a literature review to investigate the use of composite endpoints in acute heart failure and COVID-19 clinical trials. The results showed more frequent use of patient-oriented outcomes and ordinal composite endpoints in COVID-19 trials, which might be driven by global consensus on a set of common outcome measures.<\/jats:p>","DOI":"10.1017\/cts.2024.492","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T03:48:20Z","timestamp":1709869700000},"source":"Crossref","is-referenced-by-count":3,"title":["Trends in use of composite endpoints in clinical trials: A comparison between acute heart failure trials and COVID-19 trials"],"prefix":"10.1017","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-7788","authenticated-orcid":false,"given":"Lan","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-2811","authenticated-orcid":false,"given":"Christopher John","family":"Lindsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-8346","authenticated-orcid":false,"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"S2059866124004928_ref12","unstructured":"12. Food and Drug Administration. Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. FDA, 2020. (https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry). Accessed October 4, 2023."},{"key":"S2059866124004928_ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"S2059866124004928_ref14","doi-asserted-by":"publisher","DOI":"10.2307\/2531158"},{"key":"S2059866124004928_ref4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.5.1847"},{"key":"S2059866124004928_ref19","first-page":"314","article-title":"Clinical trials of pharmacological therapies in acute heart failure syndromes","volume":"3","author":"Felker","year":"2010","journal-title":"Circulation"},{"key":"S2059866124004928_ref1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6205"},{"key":"S2059866124004928_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2008.01.009"},{"key":"S2059866124004928_ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39136.682083.AE"},{"key":"S2059866124004928_ref6","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2021.13"},{"key":"S2059866124004928_ref3","doi-asserted-by":"publisher","DOI":"10.1157\/13116656"},{"key":"S2059866124004928_ref10","doi-asserted-by":"publisher","DOI":"10.1054\/jcaf.2001.25652"},{"key":"S2059866124004928_ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr352"},{"key":"S2059866124004928_ref17","unstructured":"17. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. (https:\/\/www.who.int\/docs\/default-source\/blue-print\/covid-19-therapeutic-trial-synopsis.pdf?sfvrsn=44b83344_1&download=true). Accessed October 4, 2023."},{"key":"S2059866124004928_ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00281-1"},{"key":"S2059866124004928_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"S2059866124004928_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90101-H"},{"key":"S2059866124004928_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.12.059"},{"key":"S2059866124004928_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02262-5"},{"key":"S2059866124004928_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"},{"key":"S2059866124004928_ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023538"}],"container-title":["Journal of Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2059866124004928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T08:44:56Z","timestamp":1712306696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2059866124004928\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"alternative-id":["S2059866124004928"],"URL":"https:\/\/doi.org\/10.1017\/cts.2024.492","relation":{},"ISSN":["2059-8661"],"issn-type":[{"value":"2059-8661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e55"}}